No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Rivaroxaban is partly metabolized in the liver (by CYP34A, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in the urine (by P-gp and BCRP).
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking